GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (STU:D4S) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Daiichinkyo Co (STU:D4S) Future 3-5Y EPS without NRI Growth Rate : 16.61 (As of May. 13, 2025)


View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Daiichinkyo Co's Future 3-5Y EPS without NRI Growth Rate is 16.61.

Competitive Comparison of Daiichinkyo Co's Future 3-5Y EPS without NRI Growth Rate

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Daiichinkyo Co's Future 3-5Y EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's Future 3-5Y EPS without NRI Growth Rate falls into.


;
;

Daiichinkyo Co  (STU:D4S) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Daiichinkyo Co Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Daiichinkyo Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (STU:D4S) » Definitions » Future 3-5Y EPS without NRI Growth Rate
Comparable Companies
TSE:4578 TSE:4503 TSE:4151 TSE:4528 TSE:4536 TSE:4552 TSE:4882 TSE:4519 LLY JNJ ABBV OCSE:NOVO B XSWX:ROG XSWX:NOVN LSE:AZN MRK AMGN PFE GILD XPAR:SAN
Traded in Other Exchanges
DSNKY:USA DSKYF:USA 4568:Mexico 4568:Japan
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Website
https://www.daiichisankyo.com
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co Headlines

No Headlines